Voyager Therapeutics (VYGR) Financials

Voyager Therapeutics’ latest quarter shows a company with a strong cash and investment position, but ongoing heavy losses and meaningful cash burn remain the main story. In Q1 2026, Voyager generated just $2.6 million in revenue while posting a net loss of $27.9 million. The company still has a sizable balance sheet, but it is much smaller than it was a year ago, reflecting continued use of cash to fund operations and research.

What stands out most is the decline in liquidity since early 2025. Cash and equivalents were $43.3 million at the end of Q1 2026, down from $74.8 million a year earlier and far below the more than $143 million held at the end of Q1 2024. Short-term investments also fell sharply to $98.2 million from $161.3 million a year earlier and $256.5 million in Q1 2024. Even so, Voyager still had about $171.5 million combined in cash and short- and long-term investments at quarter-end.

• The company ended Q1 2026 with about $171.7 million in cash, short-term investments and long-term investments combined, giving it a meaningful liquidity cushion.
• Voyager continues to generate some collaboration or other operating revenue, with Q1 2026 revenue of $2.6 million versus $0 cost of revenue.
• Interest and investment income of $1.9 million helped offset part of the operating loss.
• Financing activities provided $3.3 million in Q1 2026, including $3.0 million from common equity issuance.
• The company’s balance sheet still shows shareholders’ equity of $173.7 million, which is positive from a solvency perspective.
• Operating expenses remain dominated by R&D, which was $24.6 million in Q1 2026, consistent with a development-stage biotech profile.
• The company’s basic and diluted EPS were both -$0.47 in Q1 2026, similar to prior quarters, suggesting losses remain steady rather than rapidly deteriorating.
• Cash flow from investing activities was positive in Q1 2026 mainly because investment maturities exceeded new purchases, not because of core business improvement.
• Q1 2026 operating cash flow was a negative $33.4 million, highlighting a substantial ongoing cash burn from core operations.
• Revenue collapsed from $6.5 million in Q1 2025 to $2.6 million in Q1 2026, while the net loss widened slightly year over year.

Looking at the multi-year trend, Voyager’s revenue has been volatile and generally inconsistent. Quarterly revenue peaked at $90.1 million in Q4 2023, then fell sharply through 2024 and 2025 to low single-digit millions in some quarters. That kind of variability is common for biotech companies tied to milestone and collaboration payments, but it also makes earnings less predictable.

Losses have also remained persistent. Over the last several quarters, net losses have generally ranged from about $27 million to $34 million in recent quarters, after a much stronger profit in Q4 2023 driven by unusually high revenue. In other words, Voyager has not yet shown a clear path to sustained profitability.

The balance sheet trend is the main caution flag. Total assets fell from $469.6 million in Q1 2024 to $219.3 million in Q1 2026, mostly because the company spent down its cash and investment portfolio. Liabilities also declined, but equity fell from $340.9 million to $173.7 million over the same period. That is still a solid equity base, but the direction suggests continued reliance on capital markets or future collaboration payments.

Bottom line: Voyager Therapeutics remains financially positioned to keep operating for now, but investors should focus on two things: whether management can rebuild revenue through partnerships and whether cash burn starts to improve. Until that happens, the stock will likely continue to trade more like a cash-rich, event-driven biotech than a company with a stable earnings profile.